Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Coswig – page 59

1 038 clinical trials in Coswig, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Coswig at a glance
1 038
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 038 trials in Coswig

Open in trial search

Neurodermatitis

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Parkinson's disease

Not recruiting

Study on the Safety and Effects of BIIB122 for Patients with LRRK2-Associated Parkinson's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Liradasertib
  • Sponsor:Denali Therapeutics Inc.

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of Sotatercept for People with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Giant cell arteritis

Not recruiting

Study of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not recruiting

Study on BI 706321 and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 706321
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm

Not recruiting

Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Turning Point Therapeutics Inc.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Primary IgA Nephropathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Coswig

What the registry says about research in the country

01 Pulmonary Fibrosis Research

Ongoing clinical trials focusing on Progressive Pulmonary Fibrosis (PPF) and Idiopathic Pulmonary Fibrosis (IPF), evaluating innovative inhaled treatments to improve lung function and patient outcomes.

  • Inhaled Treprostinil Studies
  • Long-term Safety Evaluations
  • FVC Measurements

Multiple Phase 3 studies are examining both short and long-term treatment effects in patients with fibrotic conditions.

02 Interstitial Lung Disease Studies

Research initiatives targeting Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), with trials designed to assess new therapeutic approaches for reducing lung function decline.

  • Novel Drug Evaluations
  • Disease Progression Monitoring
  • Treatment Safety Assessments

Comprehensive studies examining both established and experimental treatments for various forms of lung fibrosis.

03 Advanced Therapeutic Development

Investigation of new compounds including bexotegrast and other innovative medications for treating various forms of pulmonary fibrosis and related conditions.

  • Placebo-controlled Studies
  • Efficacy Measurements
  • Long-term Treatment Effects

Multiple parallel studies are evaluating different therapeutic approaches to address various manifestations of fibrotic lung disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.